Peptides for Malabsorption: Clinical Approaches and Outcomes

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide therapies like Teduglutide at 0.05 mg/kg/day have shown efficacy in improving nutrient absorption in short bowel syndrome and other malabsorption states. While most patients experience enhanced intestinal adaptation, responses vary based on underlying pathology and residual bowel length.

Understanding Peptides in Malabsorption

Malabsorption syndromes, especially short bowel syndrome (SBS), often result in nutrient deficiencies due to impaired intestinal absorption. Peptides such as Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, have demonstrated efficacy in enhancing intestinal absorption by promoting mucosal growth and improving barrier function.

Mechanism of Action of GLP-2 Analogs

Teduglutide mimics endogenous GLP-2, a 33-amino-acid peptide secreted by L-cells in the distal ileum and colon. It enhances intestinal epithelial proliferation, increases villus height, and reduces gastric motility, collectively improving nutrient absorption. This peptide's half-life extends therapeutic benefits beyond native GLP-2, which has a short half-life of approximately 7 minutes.

Clinical Dosing and Administration

In clinical practice, Teduglutide is dosed at 0.05 mg/kg/day via subcutaneous injection, typically administered once daily. Treatment duration varies but often spans several months to years depending on patient response. Dose adjustments may be necessary in renal impairment, as clearance is reduced.

Clinical Evidence and Outcomes

The pivotal STEPS trial (Jeppesen et al., 2012) enrolled adult SBS patients dependent on parenteral nutrition (PN). After 24 weeks of Teduglutide therapy, 63% of patients achieved at least a 20% reduction in PN volume, with some achieving complete independence. Subsequent long-term extension studies confirmed sustained intestinal adaptation over two years.

However, response heterogeneity exists. Patients with more residual small bowel length (>100 cm) and intact colon tend to respond better. Conversely, those with extensive resections or active inflammatory bowel disease may experience less robust benefits due to diminished mucosal reserve or ongoing inflammation impairing peptide efficacy.

Comparing Peptide Therapy to Other Treatments

Traditional management focuses on optimizing nutrition, electrolyte balance, and sometimes surgical lengthening procedures. While growth factors like epidermal growth factor (EGF) and keratinocyte growth factor (KGF) have been investigated, GLP-2 analogs currently offer the most targeted and clinically validated approach.

Compared to surgical interventions, peptide therapy is less invasive and modifiable. Unlike nutritional adjustments alone, peptides directly stimulate mucosal growth rather than merely accommodating malabsorption.

Adverse Effects and Monitoring

Common side effects include abdominal pain, injection site reactions, and nausea. There is a theoretical risk of neoplasia due to trophic effects, so colonoscopy surveillance is recommended prior to and during long-term therapy, especially in patients with pre-existing polyps or inflammatory bowel disease.

Regular monitoring of fluid status, electrolytes, and liver function tests is essential, as improved absorption may unmask metabolic imbalances.

Other Peptides Under Investigation

Besides Teduglutide, peptides like Glepaglutide and Apraglutide, both GLP-2 analogs with longer half-lives, are in clinical trials aiming to improve dosing convenience and efficacy. Additionally, ghrelin analogs are being explored for their motility-enhancing and anabolic effects in malabsorption.

Clinical Nuance and Patient Selection

Not all malabsorption patients are candidates for peptide therapy. Ideal candidates include SBS patients with stable disease, dependence on PN, and residual bowel amenable to adaptation. Active inflammation, malignancy, or severe hepatic/renal disease may contraindicate use.

Moreover, some patients may require combination therapy including nutritional optimization, pharmacologic agents like antimotility drugs, and peptides for optimal outcomes.

Clinical Takeaway

In patients with malabsorption syndromes such as short bowel syndrome, initiating Teduglutide at 0.05 mg/kg/day subcutaneously can reduce parenteral nutrition dependence by enhancing intestinal absorption. Selecting patients with adequate residual bowel and minimal inflammation optimizes response. Regular monitoring for side effects and colonoscopic surveillance is essential for safe long-term use.